论文部分内容阅读
七十年代以来,国内外均应用竞争性蛋白结合分析法,直接测定体内血清总甲状腺素(简称T_4)含量,了解甲状腺机能状态。这是一种放射性体外测量的新技术,对人体无辐射危害,故对哺乳妇女及幼儿都方便。患者无需预先禁食含碘食物及药物,因而大大缩短了患者候检时间。对甲亢治疗及甲减治疗时可在不停药情况下观察疗效,及估价所用药物是否合适有较高价值,方法较简便,灵敏度高,特异性强,颇受临床工作者和患者的欢迎。
Since the seventies, competitive protein binding assay has been applied both at home and abroad to directly determine the content of total thyroxine (abbreviated as T_4) in vivo and to understand the status of thyroid function. This is a radioactive in vitro measurement of new technologies, no radiation hazards to the human body, it is convenient for lactating women and children. Patients do not need to pre-fasting foods and drugs containing iodine, thus greatly reducing the patient waiting time. Hyperthyroidism treatment and hypothyroidism treatment can be observed without stopping the case efficacy, and evaluation of the appropriate use of drugs have higher value, the method is simple, high sensitivity, specificity, popular with clinicians and patients welcome.